Literature DB >> 11257407

Adjuvants designed for veterinary and human vaccines.

J Aucouturier1, L Dupuis, V Ganne.   

Abstract

Adjuvants play an important role in the efficacy of vaccines as the antigens become more and more purified. Indeed recombinant proteins or synthetic peptides are safer than crude inactivated micro-organism, but less immunogenic. This can be balanced by specific adjuvants. But there is no universal adjuvants and their action is not yet clear and rely on different mechanisms. Then, they must be adapted according to several criteria, like the target species, the antigens, the type of immune response, the route of inoculation, or the duration of immunity. For this purpose different type of emulsions have been developed. Water in oil (W/O) emulsions induce a strong and long term immune response. Those based on mineral oils are known to be very efficient but can sometimes induce local reactions with reactive antigens. Non mineral oils are well tolerated but less efficient with poor immunogens. Multiphasic (W/O/W) emulsions can induce short and long term immune responses with various antigens and oil in water (O/W) emulsions are well tolerated and induce a short term immune response. New generation of adjuvants are based on a new concept called 'immunosol' and stem from the association of nanoparticles with a new immunostimulant. They can be used when emulsions are not suitable to obtain a good balance between safety and immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257407     DOI: 10.1016/s0264-410x(00)00498-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  70 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.

Authors:  Eva van Doorn; Heng Liu; Anke Huckriede; Eelko Hak
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

Review 3.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 4.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

5.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

7.  Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein.

Authors:  Julie Petermann; Romain Bonnefond; Isabelle Mermoud; Dewi Rantoen; Laure Meynard; Christopher Munro; Linda H L Lua; Thomas Hüe
Journal:  Exp Appl Acarol       Date:  2017-07-27       Impact factor: 2.132

8.  Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.

Authors:  Ying Xu; Enzhuo Yang; Jianguang Wang; Rui Li; Guanghua Li; Guoyuan Liu; Na Song; Qi Huang; Cong Kong; Honghai Wang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

9.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

Authors:  Bo Jin; Richard Y Wang; Qi Qiu; Fuminaka Sugauchi; Teresa Grandinetti; Harvey J Alter; J Wai-Kuo Shih
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.